Belinostat
- Generic Name
- Belinostat
- Brand Names
- Beleodaq
- Drug Type
- Small Molecule
- Chemical Formula
- C15H14N2O4S
- CAS Number
- 866323-14-0
- Unique Ingredient Identifier
- F4H96P17NZ
- Background
Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for th...
- Indication
Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline thrombocytopenia .
- Associated Conditions
- Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
- Associated Therapies
- -
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
- Conditions
- Recurrent Borderline Ovarian Surface Epithelial-Stromal TumorStage IV Borderline Ovarian Surface Epithelial-Stromal TumorStage III Borderline Ovarian Surface Epithelial-Stromal TumorStage IV Ovarian CancerFallopian Tube CarcinomaPrimary Peritoneal CarcinomaRecurrent Ovarian CarcinomaStage III Ovarian Cancer
- Interventions
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00301756
- Locations
- 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 53
- Registration Number
- NCT00274651
- Locations
- 🇺🇸
Leland Stanford Junior University, Stanford, California, United States
🇺🇸NYU Medical Center, New York, New York, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.